As PME‘s first issue of the year comes out the European pharmaceutical industry goes into 2017 steeling itself for the start of Brexit, with plenty of words already devoted to what we don’t know about the implications of the UK’s vote to leave the European Union.
This year should see the phony war end and hostilities begin in earnest when the UK formally triggers Article 50 and commences the official process of withdrawing from the EU. Read the rest of this entry »
The European Commission is not necessarily best known for its lightning reactions, but you do know that when it gets its teeth into something it’s not likely to let go.
So it may again prove to be with a technology that already seemed to be everywhere in 2016 and this year shows every sign of continuing that trend. Read the rest of this entry »
In screenwriting the three-act structure progresses from setup to confrontation to resolution, with the first act used for establishing the main characters.
It’s a device for fiction of course, but much of this year feels like just that. In fact, looking back on the last 12 months, 2016 also feels like a setup for events yet to come. Read the rest of this entry »
This month in PME we hear from the European Commissioner for Health on the burden European countries face from chronic diseases.
Dr Vytenis Andriukaitis tells of his concern about the growth in conditions such as cardiovascular diseases, cancer and type 2 diabetes, and how EU Member States need to be supported if they are to be tackled. Read the rest of this entry »
What it seems to mean, certainly in recent months, is that virtual reality is pretty much everywhere as far as media and technology efforts go. Read the rest of this entry »